JSC convened in NovemberGrindeks“Extraordinary shareholders meeting, statement said”Nasdaq Riga“.
–
Content will continue after the ad
Advertising
–
An extraordinary shareholders’ meeting has been convened by the company’s board at the request of the company’s shareholder SIA “Liplat Holding”, and it is planned to decide on the exclusion of the company’s shares from the regulated market. According to the data of the stock exchange, at the end of 2019 SIA “Liplat Holding” owned 92.81% of JSC “Grindeks” shares.
In September, the representatives of JSC “Grindeks” informed that the company has developed the development strategy of “Grindeks” group until 2025, setting the following significant development directions: expansion of the range of new active pharmaceutical ingredients and finished dosage forms; expanding into new markets – European Union countries, USA, Japan, South Korea, Australia and New Zealand; expansion of production infrastructure in Latvia; development of the subsidiary JSC “Kalceks”.
The strategy of JSC “Grindeks” envisages that the company will further focus on expanding the range of cardiovascular, central nervous system, anticancer and diabetes drugs. It is planned that in 2025 the range of products in these therapeutic groups will consist of 105 finished dosage forms, and they will be exported to 97 countries around the world. In order to strengthen its competitiveness and independence from foreign manufacturers of active pharmaceutical ingredients, it is planned to expand the range of “Grindeks” active pharmaceutical ingredients to at least 40 substances in 2025.
An important precondition for the growth of the “Grindeks” group will be the increase of the production capacity of active pharmaceutical ingredients and finished dosage forms, therefore the development plan envisages the construction of a new production plant in Latvia. Currently, the development of the project and identification of the required amount of investment has started. It is planned that the project will be implemented in several stages.
The long-term strategy of the “Grindeks” group also envisages the development of the subsidiary JSC “Kalceks”, specializing in medicines for the hospital segment. It is planned that already in 2020 “Kalceks” drug sales will reach 40 million euros.
–
–
The content of the publication or any part of it is a protected copyright object within the meaning of the Copyright Law, and its use without the permission of the publisher is prohibited. Read more here. –
